We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Projects granted during 2014 that have a primary purpose of translational and applied research: human cancer.
Government bringing together experts in the field to drive forward progress in tackling cancer in children and young people.
Innovative researchers working to tackle some of the hardest-to-treat cancers, including through the use of AI, have received a £2 million funding boost.
Estimated proportion of all malignant cancers where patients first presented as an emergency.
Projects granted during 2015 that have a primary purpose of basic research: oncology.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (11 March 2024) approved the medicine quizartinib (Vanflyta) to be used alongside chemotherapy as first line treatment for adults who have acute myeloid leukaemia (AML).
Project Orbis is a programme to review and approve promising cancer drugs helping patients access treatments faster.
Projects granted during 2014 that have a primary purpose of basic research: oncology.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.